SHENZHEN, China & ROCKVILLE, Md.–(BUSINESS WIRE)–HighTide Therapeutics Inc. (�HighTide), a clinical-stage biopharmaceutical company with novel treatments for patients with non-alcoholic steatohepatitis (NASH) and other chronic liver diseases, today announced that Liping Liu, Founder and Chief Executive Officer, and Adrian M. Di Bisceglie, Chief Medical Officer, will present virtually at the HC Wainwright 4th Annual NASH Conference on Monday, October 5, 2020 at 9:30am EDT.
About HighTide Therapeutics
HighTide Therapeutics Inc. is dedicated to the development of innovative therapeutics for people suffering from non-viral chronic liver diseases, gastrointestinal diseases and metabolic disorders with large and unmet medical needs. HTD1801 is a new molecular entity being developed for the treatment of NASH and PSC. HTD1801 has received Fast Track designation from the U.S. FDA for both NASH and PSC, as well as Orphan Drug designation for PSC. For additional information, please visit https://hightidetx.com/.
Contacts
Jeffrey Dao
ir@hightidetx.com
Ringing in the New Year, the extended collection promotes moderation and conscious drinking throughout the…
EMEISHAN, CHINA - Media OutReach Newswire - 16 December 2025 - On the evening of…
LONDON, UK - Media OutReach Newswire - 16 December 2025 - Desert diamonds graced the…
SINGAPORE - Media OutReach Newswire - 16 December 2025 - Small and Medium-Sized Accounting Practices…
SYDNEY, AUSTRALIA - Media OutReach Newswire - 16 December 2025 - Leeds Capital and MIO…
Despite 64% reporting revenue growth, 91% of merchants face payment friction HONG KONG SAR -…
